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Abstract Abnormal glycosylation of cellular glycoconjugates is
a common phenotypic change in many human tumors. Here, we
explore the possibility that an altered Golgi pH may also be
responsible for these cancer-associated glycosylation abnormal-
ities. We show that a mere dissipation of the acidic Golgi pH
results both in increased expression of some cancer-associated
carbohydrate antigens and in structural disorganization of the
Golgi apparatus in otherwise normally glycosylating cells. pH
dependence of these alterations was confirmed by showing that
an acidification-defective breast cancer cell line (MCF-7) also
displayed a fragmented Golgi apparatus, whereas the Golgi
apparatus was structurally normal in its acidification-competent
subline (MCF-7/AdrR). Acidification competence was also found
to rescue normal glycosylation potential in MCF-7/AdrR cells.
Finally, we show that abnormal glycosylation is also accom-
panied by similar structural disorganization and fragmentation
of the Golgi apparatus in colorectal cancer cells in vitro and in
vivo. These results suggest that an inappropriate Golgi pH may
indeed be responsible for the abnormal Golgi structure and
lowered glycosylation potential of the Golgi apparatus in
malignant cells. ß 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Genetic analyses of human tumors have revealed a variety
of chromosomal abnormalities, such as reassortments and de-
letions, epigenetic changes and instability of microsatellite
DNA, as well as mutations in oncogenes, tumor suppressor
genes, DNA mismatch repair enzymes and signal transduction
proteins [1^3]. In addition, about 500 di¡erentially expressed
genes have been detected in gastrointestinal cancer cells using
SAGE analysis [4]. Yet, no single consistent chromosomal
alteration or gene mutation has been detected that is inher-
ently linked to malignant transformation.
Much less is known about the many phenotypic changes
that accompany carcinogenesis. One of these is the production
and secretion of aberrantly glycosylated proteins and lipids. In
colorectal cancer, these glycosylation abnormalities are found
in most cancer patients [5^7]. They likely impair many basic
cellular functions, since terminal oligosaccharide units serve as
highly speci¢c biological recognition molecules implicated in
processes such as intracellular protein sorting, signal trans-
duction and cell^cell or cell^extracellular matrix interactions
[8]. Proliferation, di¡erentiation and metastatic properties of
cancer cells also depend on speci¢c carbohydrate structures
expressed at the cell surface [9^11]. The clinical importance
of oligosaccharide structures has also been realized recently
through identi¢cation of a number of genetic defects that
cause clinical syndromes by impairing normal glycosylation
processes [12].
Glycosylation abnormalities concern both N-linked and
O-linked carbohydrate chains on glycoproteins, and glycolip-
ids. In general, the processing of terminal sugars is mostly
a¡ected. The overall biosynthesis in malignant cells thus re-
sults in the synthesis of shorter and less branched carbohy-
drate chains, as well as in increased sialylation and reduced
sulfation [10,13,14]. Because the ¢nal structure of the oligo-
saccharide chains is mainly dictated by the activity or the
expression levels of the relevant glycosyltransferases [10,15,
16], and changes in these have been detected in human tu-
mors, they have been considered the primary cause for the
observed glycosylation abnormalities in malignant cells. How-
ever, no simple correlation between these enzymatic changes
and the ¢nal structure of the produced oligosaccharide units
has been shown to exist [17,18]. These observations, therefore,
suggest that additional possibilities may exist. In this report,
we have compared the structural and functional state of the
Golgi apparatus in di¡erent experimental systems, in an at-
tempt to assess whether an inappropriate Golgi pH could also
be responsible for these cancer-associated glycosylation ab-
normalities. Our results show for the ¢rst time that abnormal
glycosylation in malignant cells is also accompanied by a
marked disorganization of the Golgi apparatus, and that
both of these structural and functional alterations in the Golgi
apparatus can be mimicked by perturbing the existing pH in
the Golgi lumen.
2. Material and methods
2.1. Reagents
Anti-L-tubulin monoclonal antibody, rhodamine-conjugated phal-
loidin, diaminobenzidine (DAB), ammonium chloride, chloroquine,
ba¢lomycin A1, the Hoechst dye (33258), and lectin conjugates (per-
oxidase- and £uorescein-conjugated peanut agglutinin (PNA), peroxi-
dase-conjugated jacalin) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Anti-giantin monoclonal antibody was a kind
gift from Dr. H.-P. Hauri (Basel, Switzerland). Polyclonal L-COP
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antiserum was from A⁄nity Bioreagents (Golden, CO, USA). Anti-
bodies to Golgi-speci¢c ankyrin isoforms Ank119 and Ank195 were
generous gifts from Drs. J. Morrow (Yale University, New Haven,
CT, USA) and K. Beck (University of California at Davis, Davis, CA,
USA), respectively. Cancer-associated carbohydrate markers were vi-
sualized using monoclonal antibodies against the Tn and the sialosyl
Tn antigens (Calbiochem-Novabiochem, La Jolla, CA, USA), CEA
(anti-carcinoembryonic antigen; Zymed, San Francisco, CA, USA)
and CA19-9 (anti-sialyl Lewisa ; Novocastra, Newcastle upon Tyne,
UK). Alexa-488- and Alexa-594-conjugated goat anti-mouse and goat
anti-rabbit secondary antibodies were from Molecular Probes (Eu-
gene, OR, USA).
2.2. Patients
Fresh specimens of normal colorectal mucosa and carcinoma lesion
were obtained during operative surgery of patients with colorectal
carcinoma, and were processed without delay for further analyses
(see below). Samples of normal mucosa consisted of resection surfaces
at a distance of at least 10 cm from the adjacent carcinoma. Histo-
pathological diagnosis of colorectal carcinomas and the histological
grade of the tumors were con¢rmed using hematoxylin^eosin-stained
tissue sections. Written consent to use tissue lesions for research pur-
poses was obtained from each patient and accepted by the local eth-
ical committee (license 252/08/91).
2.3. Cell culture
Normal rat kidney cells (NRK) and African green monkey kidney
cells (COS-7) were grown at 37‡C, 95% air/5% CO2, in Dulbecco’s
modi¢ed Eagle’s medium (Gibco-BRL, Grand Island, NY, USA) sup-
plemented with 10% fetal calf serum and antibiotics (penicillin^strep-
tomycin). MCF-7 breast cancer cells (ATCC, Manassas, VA, USA)
and multidrug-resistant MCF-7/Adr cells (kindly provided to us by
Dr. Myles Cabot, Santa Monica, CA, USA) were grown in RPMI
1640 with the same supplements. Colorectal cancer cell lines (Caco-2,
HT-29, SW-48, T84) were cultivated on plastic dishes or glass cover-
slips in a medium suggested by ATCC. Treatment of cells with the pH
gradient dissipating drugs (chloroquine 40 WM; ammonium chloride
10^30 mM; ba¢lomycin A1 100 nM) was started 1 day after plating
by adding 100U concentrated stock solutions (in H2O; ba¢lomycin
A1 in dimethyl sulfoxide) directly into the fresh culture medium. After
6 or 20 h incubation, cells were washed, ¢xed with 2% paraformalde-
hyde, and stained with the lectins or with appropriate primary and
Alexa-conjugated secondary antibodies. All staining procedures were
done using freshly prepared 0.1% bovine serum albumin (BSA)/0.1%
saponin/phosphate-bu¡ered saline (PBS). Hoechst dye (33258, stock
solution 1 mg/ml in 50% ethanol) was diluted 1:1000 with PBS and
applied to the ¢xed cells for 2^5 min just before the ¢nal washing
steps and embedding in Immu-Mount1 (Shandon, Pittsburgh, PA,
USA).
2.4. Immunohistochemistry
A small portion of each specimen was embedded in Tissue-Tek1
(Shandon) and snap-frozen in liquid nitrogen. Frozen sections of 4 Wm
were cut and mounted on superfrost slides. The sections were post-
¢xed brie£y with 2% paraformaldehyde (in PBS) and, after quenching,
subjected to immunostaining with the anti-giantin monoclonal anti-
body (in PBS containing 3% BSA and 0.02 M glycine). Avidin^biotin
detection, using Histostain1-Plus Broad Spectrum Kit (Zymed Labo-
ratories, San Francisco, CA, USA) was then applied. DAB was used
as the chromogen and the sections were lightly counterstained with
Mayer’s hematoxylin. For control sections, the primary antibodies, or
the lectins, were replaced with PBS. A portion of each specimen was
also immediately ¢xed with 2% paraformaldehyde (in PBS) and em-
bedded in para⁄n for conventional histological and lectin staining
procedures. Peroxidase-conjugated lectins were used at a concentra-
tion of 1 Wg/ml (in 3% BSA^PBS). The sections and stained cells were
examined using an Olympus epi£uorescence microscope equipped
with a Colorview 12 CCD camera and AnalySIS software (Soft Imag-
ing System, Lakewood, CO, USA).
2.5. Transmission electron microscopy
Tissue or cell specimens were ¢xed in 2.5% glutaraldehyde (in 0.1 M
Na-phosphate bu¡er, pH 7.4). The specimens were post-¢xed in 1%
osmium tetroxide, dehydrated in acetone and embedded in Epon
LX112. Thin sections were cut with a Reichert Ultracut microtome
and examined using a Philips CM100 transmission electron micro-
scope. Epithelial cells (normal and cancer cells) were identi¢ed in
the microscope with the typical epithelial cell markers, cytokeratin
and junctional complexes. Electron microscopic images were stored
using a CCD camera.
2.6. Western blotting
Total cell lysates from either MCF-7 or MCF-7/AdrR cells were
prepared directly into Laemmli’s SDS sample bu¡er (5U106 cells in
either case). The samples were run in a 4^12% gradient gel in the
presence of SDS. After transfer onto a nitrocellulose ¢lter and
quenching with BSA, the ¢lters were probed with the antibodies
against the carbohydrate markers in 0.1% BSA and 0.1% Tween in
PBS. For visualization of the primary antibodies, a peroxidase-con-
jugated goat anti-mouse secondary antibody was used in combination
with the ECL substrates (Amersham).
3. Results
We addressed the hypothesis ¢rst by following the expres-
sion of some well-known cancer-associated carbohydrate anti-
gens in cells treated, or not, with the drugs that are known to
dissipate the existing pH gradients across cellular membranes.
The rationale of this approach was to interfere with the nor-
mal glycosylation processes in the Golgi, and to test whether
dissipation of its acidic pH (pH 6.0^6.5) could induce the
expression of cancer-associated carbohydrate antigens in nor-
mally glycosylating cell lines. As markers, we used the Thom-
sen^Friedenreich (TF or T), the Tn, and the sialosyl Tn blood
group antigens, which are expressed in over 80% of cancer
patients, but are either cryptic and concealed by further gly-
cosylation in normal epithelia [19,20]. Other markers used
included onco-developmental antigens, CEA and CA19-9.
The antigens were visualized using either the TF antigen-spe-
ci¢c lectins (PNA and jacalin) or antibodies against the Tn,
sialosyl Tn, CEA and CA19-9 antigens.
We cultured NRK and COS-7 cells either in the absence or
the in presence of chloroquine (40 WM), ammonium chloride
(10^30 mM) and a vacuolar proton ATPase inhibitor, ba¢lo-
Fig. 1. Expression of the TF antigen in NRK cells treated with pH
gradient dissipating drugs. Cells were treated for 20 h with the indi-
cated drugs, then ¢xed and stained with the £uorescein-conjugated
PNA. Note that most drug-treated cells, but not untreated cells,
show prominent expression of the TF antigen in the Golgi region,
but also in the cytoplasmic vesicles and the plasma membrane. Cells
were photographed without changing the camera settings between
di¡erent samples. Scale bar, 10 Wm.
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mycin A1 (100 nM), for 6^20 h prior to staining with the
lectins and antibodies. Indirect immuno£uorescence showed
only faint staining in untreated NRK cells (Fig. 1) and
COS-7 cells (data not shown) with either PNA or jacalin. In
contrast, drug-treated NRK cells showed a pronounced ex-
pression of the TF antigen in the Golgi region (Fig. 1), even
after 6 h treatment. After 20 h treatment (Fig. 1), the TF
antigen was still concentrated in the Golgi region, but it was
also present in small intracellular vesicles that likely represent
post-Golgi transport vesicles. The plasma membrane in drug-
treated cells was also clearly stained in a substantial portion of
the cells. Similar results were obtained with jacalin (data not
shown). The expression of the other markers (the Tn, sialosyl
Tn and CEA antigens) was also slightly increased in drug-
treated cells, whereas no change was observed in the expres-
sion of the CA19-9 antigen (data not shown). Thus, Golgi
alkalinization indeed results in increased expression of at least
some cancer-associated carbohydrate antigens in normally
glycosylating cells.
The known e¡ects of monensin (a sodium proton iono-
phore) on Golgi structure [21] prompted us to test whether
these functional changes are also accompanied by the struc-
tural disorganization of the Golgi apparatus in drug-treated
cells. We stained untreated and drug-treated NRK cells with
the anti-giantin antibody. Giantin is one of the recently char-
acterized Golgi matrix proteins [22]. We found that untreated
cells possessed a perinuclear and well organized Golgi appa-
ratus (Fig. 2, top), whereas in drug-treated cells, the Golgi
apparatus was structurally abnormal, and consisted of frag-
mented and separate Golgi elements that most often were
scattered in close proximity to the nuclei (Fig. 2). Identical
results were also observed with COS-7 cells. Electron micros-
copy revealed that the cisternae of the scattered Golgi stacks
were severely dilated in both NH4Cl- and chloroquine-treated
cells when compared to control cells (Fig. 2, bottom).
Light microscopy and counterstaining of drug-treated NRK
cells with the anti-L-tubulin antibody also revealed that micro-
tubules appeared normal and were reminiscent of those seen
in interphase cells (data not shown). Therefore, the observed
Golgi fragmentation and scattering observed in drug-treated
cells did not result from a mere accumulation of mitotic cells
with fragmented Golgi membranes. Furthermore, the frag-
mented Golgi elements also co-stained with antibodies against
L-COP, Ank119 and Ank195 (data not shown). Golgi fragmen-
tation, therefore, does not seem to involve marked changes in
the association of L-COP with the Golgi membranes, or dis-
organization of the spectrin-based Golgi membrane skeleton.
The pH dependence of these alterations in Golgi structure
and function was con¢rmed by utilizing a breast cancer cell
line, MCF-7, that is known to be unable to acidify its intra-
cellular organelles, including the Golgi apparatus [23,24]. We
found (Fig. 3) that the Golgi apparatus is heavily fragmented
and scattered in these acidi¢cation-defective breast cancer
cells. Counterstaining of MCF-7 cells with PNA showed
that these cells express the TF antigen at high levels both
intracellularly and at the plasma membrane (Fig. 3). This
was also con¢rmed by staining of MCF-7 cells without per-
meabilization (data not shown). Electron microscopy showed
further that the individual Golgi cisternae were also similarly
dilated to those seen in drug-treated NRK cells (Fig. 2), and
that only few transport vesicles were detected in close prox-
imity to the Golgi stacks (data not shown). In contrast to
these observations with MCF-7 cells, an acidi¢cation-compe-
tent subline (MCF-7/AdrR) possessed a compact, structurally
normal juxtanuclear Golgi apparatus (Fig. 3). These drug-re-
sistant cells were also found to express the TF antigen only in
the Golgi region (Fig. 3), similarly to NRK and COS-7 cells.
Other cancer-associated carbohydrate markers were also ex-
Fig. 2. Disorganization of the Golgi apparatus in cultured NRK
cells treated with the pH gradient dissipating drugs. Top: Cells were
grown on glass coverslips, treated with the drugs as above, and
stained with the anti-giantin antibody followed by Alexa 488-conju-
gated goat anti-mouse secondary antibodies. Note that the Golgi
apparatus is fragmented and scattered near the nuclei in the drug-
treated cells, but not in untreated cells. Bottom: Transmission elec-
tron microscopy of NH4Cl-treated cells and untreated NRK cells.
The micrograph shows dilatation of the cisternae of the Golgi
stacks in drug-treated cells (black arrows). In control cells, the cis-
ternae are £attened, despite the presence of some dilated vesicles on
one (trans) side of the Golgi stack. Note also the close association
of two adjacent Golgi stacks in control cells (white arrowheads).
Such an arrangement was rarely seen in drug-treated cells. Scale
bars, (top) 10 Wm, (bottom) 500 nm. N, nucleus.
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pressed at higher levels in MCF-7 cells than in MCF-7/AdrR
cells, as assessed ¢rst by immuno£uorescence. The staining
intensities of all markers tested (Fig. 4A) were clearly much
more prominent in acidi¢cation-defective MCF-7 cells than in
acidi¢cation-competent MCF-7/AdrR cells. Similar results
were also obtained by Western blotting experiments (Fig.
4B). Although all markers recognized several bands, some
of which appeared to be non-speci¢c (i.e. they were detected
using the secondary antibody alone (marked by asterisks)),
the overall intensity of the bands was clearly higher in
MCF-7 cells. Furthermore, there were several bands, includ-
ing the CEA antigen (180 kDa band in Fig. 4B), that ap-
peared to be expressed only in acidi¢cation-defective MCF-7
cells. These observations indicate that Golgi structure and
expression of cancer-associated carbohydrate structures corre-
late well not only with each other, but also with the known
ability or inability of these breast cancer cells to acidify their
intracellular organelles. Acidi¢cation competence, therefore,
appears to rescue ‘normal’ glycosylation potential in MCF-
7/AdrR cells.
The validity of these observations to colorectal cancer both
in vitro and in vivo was evaluated next by utilizing both
established colorectal cancer cell lines and colorectal tissue
specimens. Indirect immuno£uorescence experiments with
the anti-giantin antibody showed (Fig. 5) that the Golgi ap-
paratus is morphologically similar to that of acidi¢cation-de-
fective MCF-7 cells (Fig. 3), and to the drug-treated NRK
cells (Fig. 1). All these colorectal cancer cell lines possessed
a fragmented Golgi apparatus, characterized by the presence
of predominantly perinuclear (Caco-2, HT-29) and cytoplas-
mic Golgi elements (SW-48, T-84). All cell lines also expressed
cancer-associated glycosylation changes, as evidenced by their
staining with £uorescein-conjugated PNA (data not shown).
The TF antigen was also expressed at high levels in colo-
rectal cancer cells in vivo, as assessed by staining of several
cancer tissue specimens with peroxidase-conjugated PNA
(Fig. 6). The staining was evident along the whole crypt.
Higher magni¢cation (Fig. 6, top right) showed that most
Fig. 3. Golgi structure and glycosylation potential in acidi¢cation-
defective and -competent MCF-7 and MCF-7/Adr cells. Cells were
cultivated under normal cell culture conditions, ¢xed and stained
with either the anti-giantin antibody or £uorescein-conjugated PNA.
Note that in MCF-7 cells, the Golgi apparatus is heavily frag-
mented and scattered (giantin), and that the cells show prominent
expression of the TF antigen (PNA). In contrast, acidi¢cation-com-
petent MCF-7/Adr cells possess a compact juxtanuclear Golgi appa-
ratus, and the expression of the TF antigen is restricted mainly
within the juxtanuclear Golgi region. Scale bar, 10 Wm.
Fig. 4. Expression of other cancer-associated carbohydrate markers
in MCF-7 and MCF-7/AdrR cells. A: MCF-7 and MCF-7/AdrR
cells were ¢xed and stained under permeabilizing conditions with
the antibodies against known (CEA, CA19-9) cancer-associated
markers. Similar results were observed with the anti-TN and anti-
sialosyl Tn antibodies (data not shown). Scale bar, 10 Wm. B: Equal
aliquots of the cell lysates from both cell lines were run on an
SDS^PAGE gradient gel (4^12%), and after transfer to a nitrocellu-
lose ¢lter, the ¢lter was probed with the antibodies indicated. All
antibodies detected several bands in both cell lines, some of which
(e.g. the 180 kDa CEA antigen) are speci¢cally expressed only in
acidi¢cation-defective MCF-7 cells. Note also that the overall inten-
sity of the stained bands is higher in acidi¢cation-defective MCF-7
cells than in acidi¢cation-competent MCF-7/AdrR cells. The bands
marked with asterisks represent non-speci¢c bands, as they were
also detected with the secondary antibody alone. The relative mobil-
ity (kDa) of standard proteins is shown on the left.
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tumor cells were PNA-positive and that the PNA binding
glycoconjugates were present both intracellularly and in the
luminal secretions. However, not all cells within the tumor
were stained by the lectin, in agreement with the view that
tumors consist of a heterogeneous population of malignant
cells. Expression of the TF antigen in normal colorectal epi-
thelium was always faint and restricted only to the sub-apical
Golgi region (Fig. 6), as expected.
The anti-giantin antibody, which worked best on frozen
tissue sections, was used for visualization of the Golgi mem-
branes in the same PNA-positive sections. The antibody
stained a well-organized and ‘horseshoe’-shaped Golgi appa-
ratus in normal colon epithelial cells (Fig. 6, bottom left). In
cancerous epithelium, however, the Golgi apparatus was
structurally di¡erent, and consisted mainly of small punctate
structures that often were scattered around, or close to, the
nuclei (Fig. 6). Although the morphology in frozen tissue
sections is not optimal for visualization of subcellular organ-
elles, the overall microscopic appearance of the stained Golgi
elements was thus clearly reminiscent of that of the frag-
mented Golgi elements seen in acidi¢cation-defective MCF-7
cells, in all colorectal cancer cell lines and in the drug-treated
NRK cells. All four specimens that represented rectal carci-
nomas (TNM classi¢cation: three T2N0M0, grade II or III,
one T3N0M0, grade II) gave identical results.
More detailed structural analyses by transmission electron
microscopy revealed that in normal epithelial cells, the Golgi
apparatus consisted of several distinct Golgi stacks with £at-
tened cisternae, which were closely associated with each other,
usually in a curvilinear fashion (Fig. 7A). We also observed
numerous transport vesicles within the trans-Golgi area, indi-
cative of e⁄cient vesicular transport into post-Golgi destina-
tions. In contrast, the ‘fragmented’ Golgi elements in cancer
cells consisted most often of clustered Golgi stacks (Fig.
Fig. 5. Structural organization of the Golgi apparatus in colorectal
cancer cell lines. Cells were grown on coverslips under normal cell
culture conditions, ¢xed, and stained with the anti-giantin antibody.
Note that in all cell lines, the Golgi apparatus is fragmented and
scattered around the nuclei and the cytoplasm. All cell lines also ex-
pressed the TF antigen (data not shown) based on the staining with
£uorescein-conjugated PNA. Scale bar, 10 Wm.
Fig. 6. Expression of the TF antigen and the structural organization of the Golgi apparatus in colorectal cancer cells in vivo. Top: Cancer tis-
sue sections were stained with peroxidase-conjugated PNA. DAB was used as the chromogen. Note the speci¢c staining of cancerous epithelium
with the PNA (left). Only faint staining in the Golgi region is seen in normal epithelial cells (goblet cells ; right). Arrowheads point to the bor-
der between normal and cancerous tissues. Higher magni¢cation (right) shows that most cancer cells and the luminal secretions, which also
contain shed cells, express the TF antigen. Bottom: Golgi structure in normal epithelial cells. Frozen sections were ¢xed and stained with the
anti-giantin antibody followed by peroxidase-conjugated anti-mouse secondary antibodies. Note that the Golgi apparatus is well organized and
has a ‘horseshoe’-shaped con¢guration (arrows). In cancer cells (bottom right), such organization is absent, and the Golgi membranes appear
as small punctate structures around, or close to, the nuclei. Scale bars, (top) 100 Wm; (bottom) 10 Wm.
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7B,C). The stacks themselves did not show any association
with the other stacks within the same cluster. Individual Golgi
cisternae were often also dilated, showing marked swellings,
either throughout or at their rims (Fig. 7B). Other intracellu-
lar organelles, however, did not exhibit such a dilatation, and
e.g. the endoplasmic reticulum and mitochondria appeared
normal (Fig. 7C). In addition, very few transport vesicles
were detected in close proximity to the clustered and structur-
ally abnormal Golgi stacks in cancer cells. Altogether, 100
di¡erent Golgi areas were analyzed with similar results.
Jointly, Golgi fragmentation and scattering, as well as dilata-
tion of the Golgi cisternae and the presence of only few trans-
port vesicles, all appear to be characteristic features of the
Golgi apparatus in colorectal cancer cells in vivo.
4. Discussion
In this report, we followed the structural and functional
state of the Golgi apparatus in di¡erent experimental systems
that included colorectal cancer cells both in vivo and in vitro,
acidi¢cation-defective and -competent breast cancer cell lines,
and non-malignant cells that were treated (or not) with pH
gradient dissipating drugs. Our results indicate that, in all of
these experimental systems, Golgi structure and glycosylation
potential are causally related and dependent on the existing
pH gradient in the Golgi lumen. If this gradient is disturbed,
either by pH dissipating drugs or by an endogenous failure to
regulate it normally, morphologically and functionally similar
changes to those seen in colorectal cancer cells in vivo take
place. Our observations thus provide experimental evidence to
suggest that an altered Golgi pH may indeed be an additional
cause for the observed glycosylation abnormalities in malig-
nant cells.
Although direct proof for this possibility awaits the direct
in vivo measurement of the Golgi pH in malignant cells, this
possibility is intriguing, as it provides a unifying theme for a
number of seemingly unrelated observations made previously
in both malignant and non-malignant cells. For example, Gol-
gi alkalinization has been repeatedly reported to interfere with
the normal glycoprotein processing and e⁄cient vesicular traf-
¢cking through the Golgi [25^30], in agreement with our lectin
staining experiments and the morphological data. Golgi alka-
linization has also been shown to impair proper targeting of
newly synthesized proteins in the Golgi either into regulated
secretory vesicles [31] or to the apical plasma membrane in
polarized epithelial cells [32,33]. Altered Golgi pH in malig-
nant cells may therefore have direct contacts with the ob-
served dedi¡erentiation and the loss of normal cellular polar-
ity of tumor cells in vivo. Similarly, anomalous secretion of
lysosomal enzymes observed in many cancer cell types [34^36]
could simply result from missorting of these enzymes in the
Golgi due to an inappropriate Golgi pH.
Fig. 7. Transmission electron microscopy of the Golgi apparatus in
colorectal cancer cells in vivo. A: Normal tissue. The electron mi-
crograph shows the well-organized Golgi stacks and their close asso-
ciation with each other (arrowheads). Note also the trans-Golgi area
which is ¢lled with numerous vesicles, indicative of e⁄cient vesicular
tra⁄cking in this region (arrows). B,C: Cancerous epithelial cells.
Note the lack of linear organization of the individual Golgi stacks
in cancer cells. The stacks are most often clustered together in a
random fashion, often facing perpendicular to each other (B). The
cisternae are also dilated, either throughout or at their rims (B).
Note also the presence of only few Golgi-associated transport
vesicles in cancer cells (B, C, arrows). The rough endoplasmic retic-
ulum (rER) and mitochondria (m) appear normal. Asterisks indicate
the concave (trans) side of the Golgi stacks (C). Scale bar, 1 Wm.
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Direct pH measurements have also shown that alterations
in intracellular and extracellular pH homeostasis are common
in tumor cells [37,38]. Previous studies on multidrug resistance
have also shown that the major di¡erence between drug-sen-
sitive and -resistant cells is their ability or inability, respec-
tively, to acidify their intracellular organelles [23,24], and be-
cause most tumors in vivo can be successfully treated with
chemotherapeutic drugs, such alterations in the pH homeo-
stasis appear to be common in intracellular organelles as well.
Such alterations may even be intimately associated with ma-
lignant transformation itself, since transformation of mamma-
lian cells with the yeast plasma membrane H-ATPase or with
certain viral oncogenes has been shown to correlate with al-
kalinization of either the cytoplasm [39^41], the Golgi lumen
[42], or the lysosomes [43]. In addition, acidic extracellular pH
has been shown to alter the gene expression pro¢le [44], and
to increase the mutation rate by impairing DNA repair [45].
Exactly how an altered Golgi pH may interfere with the
normal glycosylation processes is not known. One possibility
could be that Golgi alkalinization may simply reduce the ac-
tivity of the relevant glycosyltransferases, since late-acting
Golgi glycosyltransferases are known to have their pH optima
at a slightly acidic pH range ([15] and references therein).
However, it is not clear how such a reduction in the enzymatic
activity alone would result simultaneously in the structural
disorganization of the Golgi in tumor cells (Figs. 3, 5^7).
Therefore, additional factors are likely to be involved, and
one such factor could be an altered Golgi pH which, by im-
pairing balanced membrane £ow through the Golgi, would
interfere not only with the structural organization of the Gol-
gi, but also with the observed recycling of glycosyltransferases
between the endoplasmic reticulum and the Golgi, thereby
causing their mislocalization and inability to modify their sub-
strates correctly. Consistent with this scenario, a 130 kDa cis-
Golgi resident protein has been shown to be mislocalized in
colorectal cancer cells in vivo [46], and in cultured cells, tar-
geted mislocalization of a late-acting Golgi glycosyltransferase
to the cis-Golgi has been shown to inhibit the synthesis of
branched O-glycans [47]. Very recently, Golgi alkalinization
has indeed been shown to result in mistargeting of middle- or
trans-Golgi glycosyltransferases into endosomes and the plas-
ma membrane [48].
The results of this study raise several important questions
that concern not only the in vivo measurement of the Golgi
pH in malignant cells, but also the mechanistic details and the
identity of the ion transporter(s) that may be responsible for
the suggested pH alterations in the Golgi lumen. Because
Golgi pH is known to be ¢nely regulated, any perturbations
in it may involve changes in either the rate of proton pump-
ing, proton leakage, counterion (Cl3) transport, or even im-
port or export of base equivalents across the Golgi mem-
branes [49^51]. In this context, it should be emphasized that
the Golgi pH in cancer cells could also be more acidic than
the pH in non-malignant cells. This possibility, however, was
not addressed here. Since the existing pH in the Golgi lumen
may also depend on cytoplasmic and extracellular pH gra-
dients, potential ion transporter(s) that may be defective (or
remain constantly active) in malignant cells are numerous.
The most likely candidates, in addition to the vacuolar H-
ATPase [52], are the Golgi-associated chloride channel [53],
the Na/H antiporter [54], and the sodium-dependent and -
independent chloride/bicarbonate exchangers, such as the
DRA (down-regulated in adenoma gene product [55]) and the
Golgi-associated Cl3/HCO33 exchanger recently identi¢ed by
us [56]. The major challenge in the future studies, therefore, is
to assess whether any one of these is defective in malignant
cells.
5. Note
During the preparation of this article, we became aware of
a recent article in which the authors [Campbell, B.J., Rowe,
G.E., Leiper, K. and Rhodes, J.M. (2001) Glycobiology 11,
385^393] show that neutralization of intra-Golgi pH with ba-
¢lomycin in LS174T cells increases TF antigen expression and
reduces mucin sulfation. The results are fully compatible with
the lectin binding data presented in this article.
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